<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622075</url>
  </required_header>
  <id_info>
    <org_study_id>AE-V-S-1001</org_study_id>
    <nct_id>NCT01622075</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent</brief_title>
  <acronym>PEPCAD</acronym>
  <official_title>A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical International Trading Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Medical International Trading Company Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of successful interventional&#xD;
      therapy and unblocked blood vessel maintaining in the treatment of coronary in-stent&#xD;
      restenosis by paclitaxel -eluting PTCA- balloon catheter (3μg/mm2 balloon surface area)&#xD;
      versus paclitaxel-eluting stent Taxus® Liberte, and the reference diameter of coronary artery&#xD;
      stenosis is 2.5mm-4.0mm and the length ≤30mm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss in segment section at M9</measure>
    <time_frame>One year</time_frame>
    <description>To measure the diameter loss in segment restenosis of the target lesion vessel by using angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of the interventional therapy</measure>
    <time_frame>Two year</time_frame>
    <description>To compare the successful treatment of coronary artery stent restenosis intervention between Paclitaxel release PTCA balloon and Taxus® Liberte, including apparatus success, lesion success and clinical success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes of clinical follow-up visits for drug stent versus drug balloon</measure>
    <time_frame>Two year</time_frame>
    <description>Binary restenosis rate in lesion section at M9&#xD;
Cardiovascular clinical composite endpoints related to apparatus at D30, M6, M9, M12 and M24, including cardiac death, target blood vessel myocardial infarction and target lesion vessel revascularization driven by clinical symptoms, briefed as target lesion failure&#xD;
Cardiovascular clinical composite endpoints related to patients at D30, M6, M9, M12 and M24, including all-cause death, all myocardial infarction and any vessel revascularization&#xD;
Thrombus event rate defined by ARC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Coronary Instent Restenosis</condition>
  <arm_group>
    <arm_group_label>SeQuent® Please</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel Drug-eluting Coronary Artery Balloon Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxus Liberte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel Drug-eluting Coronary Stent and Conveying System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent® Please</intervention_name>
    <description>SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial</description>
    <arm_group_label>SeQuent® Please</arm_group_label>
    <other_name>Paclitaxel Drug-eluting Coronary Artery Balloon Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus Liberte</intervention_name>
    <description>Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial</description>
    <arm_group_label>Taxus Liberte</arm_group_label>
    <other_name>Paclitaxel Drug-eluting Coronary Stent and Conveying System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Related to patients&#xD;
&#xD;
               -  Patients with stable angina, unstable angina, old myocardial infarction or proven&#xD;
                  asymptomatic ischemia&#xD;
&#xD;
               -  Restenosis after the first stent implant&#xD;
&#xD;
               -  Patients who can receive any kind of coronary revascularization (including&#xD;
                  balloon angioplasty, stent implantation or coronary artery bypass grafting)&#xD;
&#xD;
               -  Patient aged 18-80 (including 18 and 80)&#xD;
&#xD;
               -  Female patients of childbearing age in the study period shall not be pregnant or&#xD;
                  protocol to be pregnant, it is suggested that patients shall take sufficient&#xD;
                  contraception measures till (including) the follow-up visit of month 9&#xD;
&#xD;
               -  Patients who agree to accept the angiography follow-up visits of month 9&#xD;
&#xD;
               -  Patients who agree to accept the clinical visits at Day 30, Month 6 and Month 12&#xD;
&#xD;
               -  Patients can understand the study objectives psychologically and linguistically&#xD;
                  and show the sufficient compliance to the study protocol. Patients present&#xD;
                  acceptance of the risks and benefits described in the informed consent form.&#xD;
&#xD;
          2. Related to lesion&#xD;
&#xD;
               -  Drug-eluting stent restenosis: Type Mehran I, Type II and Type III; the reference&#xD;
                  blood vessel diameter is 2.5 mm-4.0 mm, length ≤30mm&#xD;
&#xD;
               -  Before surgery, stenosis diameter must be ≥70% or ≥50% and accompanied by&#xD;
                  ischemia&#xD;
&#xD;
               -  The distance between other lesion requires interventional therapy and the target&#xD;
                  lesion must be &gt;10mm&#xD;
&#xD;
               -  In the stent group, up to two paclitaxel drug stents are permitted to be&#xD;
                  implanted in series&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Related to patients&#xD;
&#xD;
               -  Patients with myocardial infarction within one week&#xD;
&#xD;
               -  Patients with severe congestive heart failure or NYHA IV severe heart failure&#xD;
&#xD;
               -  Patients with severe valvular heart disease&#xD;
&#xD;
               -  Female patients in pregnancy or lactation&#xD;
&#xD;
               -  Patients with the life expectancy not exceeding 1 year or the factors causing&#xD;
                  difficult clinical follow-up visits&#xD;
&#xD;
               -  Patients with hemorrhagic tendency, prohibited to take anticoagulants or&#xD;
                  antiplatelet drugs&#xD;
&#xD;
               -  Patients with stroke within 6 months before the surgery&#xD;
&#xD;
               -  Patients taking part in any other clinical tests&#xD;
&#xD;
               -  Existing sever renal failure (GFR&lt;30ml/min) or the history, so not meeting the&#xD;
                  conditions of angiography&#xD;
&#xD;
               -  Patients with cardiac transplantation&#xD;
&#xD;
               -  Patients not included for other reasons from the investigators&#xD;
&#xD;
          2. Related to lesion&#xD;
&#xD;
               -  Evidence of extensive thrombus in target blood vessel before the intervention&#xD;
&#xD;
               -  Percutaneous coronary intervention for many in-stent restenosis lesions in same&#xD;
                  artery&#xD;
&#xD;
               -  3-vessel disease that all need to be intervented&#xD;
&#xD;
               -  In bifurcation lesions, branch open blood vessel diameter ≥2.5mm&#xD;
&#xD;
               -  Percutaneous coronary intervention of venous graft&#xD;
&#xD;
               -  Entire shut of Grade TIMI 0 blood flow (Type Mehran IV stenosis)&#xD;
&#xD;
               -  Open lesion at left primary and within 2mm&#xD;
&#xD;
          3. Related to concomitant therapy&#xD;
&#xD;
               -  Patients cannot tolerate aspirin and/or clopidogrel, patients with the history of&#xD;
                  neutrocytopenia or thrombocytopenia, or patients with severe hypohepatia and&#xD;
                  prohibited to take clopidogrel&#xD;
&#xD;
               -  Patients known allergic to paclitaxel&#xD;
&#xD;
               -  Patients with the history of leucopenia (numeration of leukocytes &lt;3x109/L,&#xD;
                  exceeding 3 days), neutrocytopenia (ANC&lt;1000 neutrocytes/mm3, exceeding 3 days)&#xD;
                  or thrombocytopenia (&lt;100,000 platelets/mm3&#xD;
&#xD;
               -  Patients with the history of peptic ulcer or gastrointestinal hemorrhage in the&#xD;
                  past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai CVD Hospital of Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai CVD Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

